D-0144-2026 Class II Ongoing

Recalled by SUN PHARMACEUTICAL INDUSTRIES INC — Princeton, NJ

FDA drug recall D-0144-2026 was initiated by SUN PHARMACEUTICAL INDUSTRIES INC on Oct 28, 2025 and is designated Class II. Reason for recall: Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate… The recall status is ongoing.

Recall details

Product Type
Drugs
Report Date
Nov 5, 2025
Initiation Date
Oct 28, 2025
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Lisdexamfetamine Dimesylate Capsules, 10 mg, CII, 100-count bottle, Rx only, Manufactured by: OHM Laboratories, New Brunswick, NJ 08901, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, NDC 57664-046-88.

Reason for recall

Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate capsules.

Distribution pattern

U.S Nationwide.

Code information

Lot #: AD42468, Expiry: 2/28/2026; AD48705, Expiry: 4/30/2026.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0144-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0144-2026. Report a data issue: hello@regdatalab.com.